Author argues Sana Biotechnology's immune-evasive insulin-producing islets achieved 1-year survival without immunosuppression, positioning it as a potential first-to-market type 1 diabetes cure.
SANA — LONG Sana Biotechnology announced that its engineered insulin-producing islets survived in a human for 1 year without immunosuppression, validating its immune-evasive anti-rejection technology. The author argues this positions Sana to be first to market by several years for a type 1 diabetes cure, with a phase 1 trial of lab-grown insulin-producing cells starting this year. The author notes insulin expression was reduced at 52 weeks, attributed to donor islet age, but no rejection was observed.
Sana's immune evasion technology solves this problem, avoiding the need for immunosuppression altogether.
This Reddit post, published January 14, 2026, features u/Intrepid_Web5454 discussing SANA. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Intrepid_Web5454 · Tickers: SANA